BIIB - BIOGEN INC.
150.38
3.010 2.002%
Share volume: 2,925,462
Last Updated: 03-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.02%
PREVIOUS CLOSE
CHG
CHG%
$147.37
3.01
0.02%
Fundamental analysis
58%
Profitability
84%
Dept financing
29%
Liquidity
12%
Performance
51%
Performance
5 Days
2.04%
1 Month
7.88%
3 Months
-4.50%
6 Months
-24.47%
1 Year
-34.64%
2 Year
-41.84%
Key data
Stock price
$150.38
DAY RANGE
$146.63 - $154.29
52 WEEK RANGE
$128.51 - $238.00
52 WEEK CHANGE
-$33.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Christopher A. Viehbacher
Region: US
Website: biogen.com
Employees: 8,720
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: biogen.com
Employees: 8,720
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. It also offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and pemphigus vulgaris.
Recent news